Pfenex Inc. Watch

from 10-Q 4 pages Amendments to the Development Agreement

from 10-Q 4 pages Amendment No. 3 to the Development and License Agreement

from 10-Q 10 pages Deed of Assignment and Amendment

from 10-Q 1 page Certain Confidential Information Contained in This Document Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Has Been Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. April 27, 2020 Alvogen Malta (Out-Licensing) Ltd. Malta Life Sciences Park, Sir Temi Zammit Buildings, Level 4, Building 1, San Gwann Industrial Estate, Sgn 3000, Malta Attention: Legal via Email Re: Development and License Agreement Dated February 25, 2019 (As Previously Amended, the “Row Agreement”) Between Pfenex Inc. (“Pfenex”) and Alvogen Malta (Out-Licensing) Ltd. (“Alvogen”) Dear Edin,

from 10-Q 3 pages Amendment No. 2 to the Development and License Agreement

from 10-K 19 pages Transition Agreement and Limited Release

from 10-K 3 pages Certain Confidential Information Contained in This Document Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Has Been Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendment No. 1 to the Development and License Agreement

from 10-Q 13 pages Pfenex Inc. Executive Employment Agreement

from 10-Q 6 pages Definitions

from 10-Q 72 pages Certain Confidential Information Contained in This Document Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Has Been Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. E.U. Development and License Agreement by and Between Pfenex Inc. and Alvogen Malta (Out-Licensing) Ltd. February 25, 2019

from 10-Q 67 pages Certain Confidential Information Contained in This Document Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Has Been Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Mena Development and License Agreement by and Between Pfenex Inc. and Alvogen Malta (Out-Licensing) Ltd. February 25, 2019

from 10-Q 68 pages Certain Confidential Information Contained in This Document Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Has Been Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Development and License Agreement by and Between Pfenex Inc. and Alvogen Malta (Out-Licensing) Ltd. February 25, 2019

from 8-K 36 pages Pfenex Inc. 2014 Equity Incentive Plan

from 10-Q 4 pages Confidential Portions of This Document Have Been Redacted and Have Been Separately Filed With the Securities and Exchange Commission. Information That Was Omitted in the Edgar Version Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”

from 10-Q 14 pages Transition Agreement and Release

from 8-K 12 pages Pfenex Inc. Executive Employment Agreement

from 10-Q 70 pages Development and License Agreement by and Between Pfenex Inc. and Alvogen Malta Operations Ltd. June 11, 2018

from 10-Q 4 pages Confidential Portions of This Document Have Been Redacted and Have Been Separately Filed With the Securities and Exchange Commission. Information That Was Omitted in the Edgar Version Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendment of Solicitation/Modification of Contract 1. Contract Id Code Page of Pages 1 18

from 10-Q 67 pages Development and License Agreement by and Between Pfenex Inc. and China Nt Pharma Group Company Ltd. April 18, 2018

from 10-K/A 87 pages Amended and Restated License and Option Agreement